James K. Hennan - Concepedia

Author

James K. Hennan

Also Known As

Hennan, J., Hennan, James, Hennan, James Kenneth, J K Hennan, J. Hennan, J.K. HENNAN, J.K. Hennan, JAMES K. HENNAN, James Hennan, James K Hennan

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Zealand Pharma (Denmark)Bristol-Myers Squibb (United States)University of Michigan Women's Health Research Institute University of Copenhagen

About

James K. Hennan is an author at Zealand Pharma (Denmark) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	726
2	Natural Sciences	3	3	224
3	Public Health	3	3	93
4	Engineering	1	1	13
5	Anesthesia	1	1	23

James K. Hennan

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Tiplaxtinin, a Novel, Orally Efficacious Inhibitor of Plasminogen Activator Inhibitor-1: Design, Synthesis, and Preclinical Characterization Hassan Elokdah, Magid Abou‐Gharbia, James K. Hennan, Journal of Medicinal Chemistry Pharmaceutical ScienceAntiparasitic AgentCardiovascular PharmacologyPharmacotherapyPharmaceutical Chemistry	2004	166
Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries James K. Hennan, Jinbao Huang, Terrance D. Barrett, Circulation	2001	162
Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123) Lene Nygaard Axelsen, Martin Stahlhut, Shabaz Mohammed, Journal of Molecular and Cellular Cardiology Signal TransductionBiochemistryG Protein-coupled ReceptorMedicinePossible Target	2006	133
Model-Dependent Effects of the Gap Junction Conduction–Enhancing Antiarrhythmic Peptide Rotigaptide (ZP123) on Experimental Atrial Fibrillation in Dogs Akiko Shiroshita-Takeshita, Masao Sakabe, Ketil Haugan, Circulation	2007	132
C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion Terrance D. Barrett, James K. Hennan, Rory M. Marks, Journal of Pharmacology and Experimental Therapeutics	2002	92
Rotigaptide (ZP123) Prevents Spontaneous Ventricular Arrhythmias and Reduces Infarct Size During Myocardial Ischemia/Reperfusion Injury in Open-Chest Dogs James K. Hennan, Robert E. Swillo, Gwen A. Morgan, Journal of Pharmacology and Experimental Therapeutics	2006	85
The Antiarrhythmic Peptide Analog ZP123 Prevents Atrial Conduction Slowing During Metabolic Stress Ketil Haugan, Kristine Boisen Olsen, Line Hartvig, Journal of Cardiovascular Electrophysiology	2005	71
Effect of tiplaxtinin (PAI‐039), an orally bioavailable PAI‐1 antagonist, in a rat model of thrombosis James K. Hennan, Gwen A. Morgan, Robert E. Swillo, Journal of Thrombosis and Haemostasis ThrombopoiesisThrombosisMolecular PharmacologyMedicinePharmacotherapy	2008	62
Effects of Chronic Gap Junction Conduction–Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs Gabriel Laurent, Howard Leong‐Poi, Iqwal Mangat, Circulation Arrhythmia and Electrophysiology Electrophysiological EvaluationCardiovascular DiseaseMedicinePhysiologyExperimental Atrial Fibrillation	2009	54
The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model Eric I. Rossman, Kun Liu, Gwen A. Morgan, Journal of Pharmacology and Experimental Therapeutics	2009	53

Page 1